{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 67,
  "pageCount": 415,
  "prevPage": 66,
  "nextPage": 68,
  "slideType": "nominee_bio",
  "function": "introduce_nominees",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide presents critical expert feedback on drug formulation and safety protocols.",
  "elementsJson": [
    "headline_text",
    "bullet_list"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/67",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-67",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Stated that diazoxide can be fatal and is contraindicated in patients with elevated pulmonary pressures - common in PWS patients due to obesity and diabetes, both of which greatly increase risk of increased pulmonary hypertension",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b29a-2d1302d9bd65",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.85,
        "x": 0.07,
        "y": 0.21
      },
      "kind": "list",
      "text": "Stated that diazoxide can be fatal and is contraindicated in patients with elevated pulmonary pressures. The investigator indicated that ongoing echocardiograms are mandatory if using Vykat. Stated that regular diazoxide suspension is vastly superior to Vykat’s pill formulation. Emphasized repeatedly that regular diazoxide suspension is “always going to be better” than Vykat tablets.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6469e725-7dbd-4726-8b1b-f3a3c4ba0713",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“that’s why they have to stop using diazoxide...it can be devastating...that would be my worry.” — Trial investigator #6",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64ce-7561-b29a-33fc1a8aae22",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Scorpion Capital consultation calls with experts",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a54e75b4-7f5e-41f1-8954-0438567d1284",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "Trial investigator #6 (cont’d): Clinician and researcher with ~30-35 PWS patients and participated in the phase 3, open-label, and withdrawal studies.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e834ba3-9a58-4f4e-8154-b8346feba573",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Anadiplosis",
      "slug": "anadiplosis",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "5e377520-d718-434e-9c7a-98096bf4fd11",
      "evidence": "Stated that diazoxide can be fatal and is contraindicated in patients with elevated pulmonary pressures - common in PWS patients due to obesity and diabetes, both of which greatly increase risk of increased pulm",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}